Last reviewed · How we verify
Intermittent PD-1 inhibitor therapy
Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern.
Intermittent PD-1 inhibitor therapy blocks the PD-1 checkpoint protein on immune cells periodically, allowing the immune system to recognize and attack cancer cells in a cyclical dosing pattern. Used for Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials).
At a glance
| Generic name | Intermittent PD-1 inhibitor therapy |
|---|---|
| Sponsor | Canadian Cancer Trials Group |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PD-1 inhibitors work by releasing the brakes on T cells that have been exhausted by chronic tumor antigen exposure. By administering these inhibitors intermittently rather than continuously, this approach aims to optimize immune activation while potentially reducing cumulative toxicity and allowing immune system recovery between treatment cycles.
Approved indications
- Advanced or metastatic cancer (specific tumor types under investigation in phase 3 trials)
Common side effects
- Fatigue
- Immune-related adverse events (irAEs)
- Pneumonitis
- Hepatotoxicity
- Colitis
Key clinical trials
- Duration of Anti-PD-1 Therapy in Metastatic Melanoma (PHASE3)
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy (PHASE1)
- PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk (PHASE2)
- Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intermittent PD-1 inhibitor therapy CI brief — competitive landscape report
- Intermittent PD-1 inhibitor therapy updates RSS · CI watch RSS
- Canadian Cancer Trials Group portfolio CI